Does Medicaid Cover Wegovy? The State Patchwork for Obesity Coverage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

As of May 2026. Confirm directly with your state Medicaid program. Coverage varies by state, by MCO, and by time. Always confirm with your specific Medicaid agency.

Key Takeaways

• State Medicaid coverage of Wegovy for obesity varies sharply. About 14 states cover GLP-1 medications for weight loss as of May 2026; the rest restrict or exclude
• The federal Part D weight-loss exclusion does not apply to Medicaid. States choose whether to cover weight-loss drugs
• States that cover Wegovy require PA with BMI documentation, comorbidity (for BMI 27 to 29.9), and lifestyle intervention
• Renewal typically requires 5% weight loss from baseline at 6 months
• The Medicaid Fair Hearing is the federally protected appeal path. Decisions are binding on the state Medicaid agency

Direct answer

Medicaid coverage of Wegovy for chronic weight management depends on the state. As of May 2026, roughly 14 state Medicaid programs cover Wegovy or other GLP-1 medications for obesity, with the rest either restricting coverage to narrow circumstances or excluding weight-loss drugs entirely. In states that cover Wegovy, PA criteria require BMI 30 or higher or BMI 27 or higher with comorbidity, lifestyle intervention documentation, and age 18 or older. Medicaid copays are minimal where coverage exists.

Table of contents

1. How Medicaid drug coverage works for weight-loss medications
2. The federal framework: Medicaid Drug Rebate Program and state choice
3. States that cover Wegovy for obesity
4. States that restrict or exclude Wegovy coverage
5. PA criteria patterns across covering states
6. Step therapy and lifestyle intervention
7. Renewal criteria: the 5% threshold
8. Medicaid managed care: MCO variation within a state
9. Copays and federal limits
10. Medicaid Fair Hearings: the appeal path
11. Dual-eligible beneficiaries and the CMS rule
12. The budget tension that drives state decisions
13. When Medicaid won't cover: alternatives including 503A compounded
14. Contrary view: the case for Medicaid caution on Wegovy
15. Decision framework
16. FAQ
17. Sources

How Medicaid drug coverage works for weight-loss medications

Medicaid is a federal-state partnership. CMS sets baseline rules and provides matching funds; states administer the program. For prescription drugs, the federal Medicaid Drug Rebate Program requires manufacturers to give Medicaid the lowest negotiated price they offer commercially in exchange for Medicaid coverage of their drugs.

The federal Part D weight-loss exclusion that applies to Medicare does not apply to Medicaid. Each state chooses whether to cover weight-loss drugs. Some states have covered Saxenda, Wegovy, Qsymia, Contrave, and other obesity medications for years. Others have excluded weight-loss drugs since the Medicaid drug benefit began.

The federal framework: Medicaid Drug Rebate Program and state choice

The Medicaid Drug Rebate Program covers drugs from participating manufacturers. Wegovy is on the Medicaid Drug Rebate Program list. This means any state Medicaid program that chooses to cover Wegovy can do so, and receives the manufacturer rebate.

States make coverage decisions through:

• Preferred drug list (PDL) decisions
• PA criteria
• Step therapy
• Quantity limits
• Exclusion of categories (some states exclude weight-loss drugs entirely)

State Medicaid pharmacy bulletins publish the current decisions. Bulletins update as state policies change.

States that cover Wegovy for obesity

As of May 2026, the following states have covered Wegovy or other GLP-1 medications for obesity in their Medicaid programs (this list shifts; current state bulletins are authoritative):

• Massachusetts
• Minnesota
• Pennsylvania
• California (in some MCOs and through specific PA pathways)
• Michigan
• Wisconsin
• Virginia
• New York (with PA and specific criteria)
• Illinois
• New Hampshire
• Oregon (with PA)
• Rhode Island
• Vermont
• Washington (with PA)

Coverage details vary. Some states cover Wegovy as the preferred GLP-1 for obesity; others prefer Saxenda first via step therapy. Some require participation in a state-approved weight-management program. The state Medicaid pharmacy bulletin is the operative document.

States that restrict or exclude Wegovy coverage

States that have not covered Wegovy for obesity or that maintain a categorical exclusion of weight-loss drugs (subject to change):

• Texas
• Florida
• Tennessee
• Mississippi
• Louisiana
• Alabama
• Georgia (with limited exceptions)
• Oklahoma
• South Carolina

Some of these states cover Wegovy for the November 2024 CMS rule cardiovascular indication for dual-eligibles who have established cardiovascular disease. Some have considered adding obesity coverage but have not enacted.

PA criteria patterns across covering states

In states that cover Wegovy, the PA pattern is consistent in shape:

• BMI documented with measurement date
• BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity
• Age 18 or older for adult indication; pediatric criteria for ages 12 to 17
• Documentation of prior weight-loss attempts (often 3 to 6 months of lifestyle intervention)
• Sometimes participation in a state-approved weight-management program
• Step therapy with Saxenda or another agent on some state PDLs

Initial approvals are typically 6 months. Renewal requires documented weight loss.

Step therapy and lifestyle intervention

Step therapy is common in Medicaid for cost reasons. For Wegovy, the most frequent step is Saxenda (liraglutide) given the same drug class and lower per-fill cost. Some states also require trial of phentermine, Qsymia, or Contrave before Wegovy on the obesity PDL.

Lifestyle intervention documentation varies in the form accepted:

• Dietitian or nutritionist visit records
• Commercial program enrollment (some states)
• State or local weight-management program participation
• Chart notes from primary care visits addressing weight

The duration requirement ranges from 3 to 6 months prior or concurrent depending on the state.

Renewal criteria: the 5% threshold

Most state Medicaid PAs require 5% weight loss from baseline at 6 months for renewal. This matches FDA labeling guidance for continuation of obesity pharmacotherapy.

Renewal documentation:

• Baseline weight (from start of therapy)
• Current weight
• Percentage weight loss
• Continued lifestyle engagement
• Continued tolerability and lack of significant adverse effects

Patients who do not meet the threshold may be declined renewal in many states. Some states allow continued therapy with documented dose-titration trajectory or alternative clinical justification.

Medicaid managed care: MCO variation within a state

Most state Medicaid enrollees are in managed care organizations. Major Medicaid MCOs include Centene, Molina Healthcare, UnitedHealthcare Community Plan, Anthem Medicaid plans, Aetna Better Health, and state-specific MCOs.

Within a state that covers Wegovy, individual MCOs may apply their own PA criteria or step therapy within the state-approved framework. Two enrollees in the same state can face different coverage details if they are in different MCOs.

The state Medicaid agency sets the floor. MCOs work within it.

Copays and federal limits

Federal Medicaid rules limit copays. Most state Medicaid programs charge $0 to $8 per prescription. Children, pregnant women, and people in long-term care facilities are exempt.

Federal law prohibits Medicaid pharmacies from withholding a medically necessary drug if the patient cannot pay the copay at the counter. The pharmacy must dispense and bill the patient later.

Medicaid Fair Hearings: the appeal path

Medicaid beneficiaries have a federal right to a Fair Hearing when a benefit is denied, reduced, or terminated. The process:

1. The denial notice from the MCO or state Medicaid agency includes the Fair Hearing request form and deadline (60 to 90 days)
2. You request the hearing in writing or by phone
3. The MCO or state must continue the benefit pending the hearing if you request it within the timely-filing window (usually 10 days from the notice)
4. The hearing is held by phone or in person within 90 days
5. You present evidence: medical records, prescriber letter, plan policy
6. The decision arrives in writing, typically within 30 days of the hearing

If unfavorable, judicial review in state court may be available. Many MCO denials reverse before the hearing once the state Medicaid agency reviews the file.

Dual-eligible beneficiaries and the CMS rule

Dual-eligibles have both Medicare and Medicaid. For Wegovy:

• If the patient has established cardiovascular disease, Part D may cover Wegovy under the November 2024 CMS rule. Medicaid wraps around for cost-sharing
• If the patient does not have CVD but has obesity, Part D does not cover. State Medicaid may cover in covering states; in non-covering states, no coverage path exists through public benefits

The path depends on the state and the clinical situation.

The budget tension that drives state decisions

State Medicaid programs operate on annual budgets approved by state legislatures. Adding broad GLP-1 weight-loss coverage to a state Medicaid program is a meaningful new expenditure. State legislatures weigh this against competing priorities.

Arguments that have driven states toward coverage:

• Documented cardiovascular and renal benefits beyond pure weight management
• Recognition of obesity as a chronic disease with downstream Medicaid costs
• Equity concerns about access to medications widely available to commercial enrollees

Arguments that have driven states away from coverage:

• Annual budget constraints
• Cost-effectiveness analyses with mixed conclusions
• Concerns about long-term adherence and discontinuation rebound
• Competing priorities for limited Medicaid dollars

When Medicaid won't cover: alternatives including 503A compounded

For Medicaid beneficiaries in non-covering states or with denied PAs:

• The Novo Nordisk patient assistance program for income-qualified patients
• The Wegovy Savings Card is not available to Medicaid beneficiaries
• 503A compounded semaglutide via telehealth (cash-pay, not billable to Medicaid)

The PAP income threshold (approximately 400% of FPL as of 2026) is well above Medicaid eligibility income, so PAP eligibility is easier than for some commercial enrollees. The application is direct to Novo Nordisk.

503A compounded semaglutide is prepared individually by a state-licensed 503A pharmacy. It is not FDA-approved, not equivalent to brand-name Wegovy, and not billable to Medicaid. FormBlends works with state-licensed 503A pharmacies and licensed clinicians.

For Medicaid beneficiaries who could not afford even compounded medication, the brand-name PAP is usually the better starting point.

Contrary view: the case for Medicaid caution on Wegovy

The Medicaid Wegovy coverage patchwork frustrates beneficiaries and advocates. The defense rests on the reality of state budget constraints.

Adding broad GLP-1 weight-loss coverage to a state Medicaid program requires the state to either reduce other spending or raise revenue. Both are politically costly. The CBO has not produced state-level estimates, but rough projections suggest GLP-1 weight-loss coverage in a typical state Medicaid program would add tens of millions to hundreds of millions in annual spending depending on state size and uptake.

The case for coverage rests on downstream savings: reduced cardiovascular disease, reduced kidney disease, reduced diabetes complications. The evidence base for these savings is growing but still incomplete in Medicaid populations specifically, where adherence and follow-up are less consistent than in commercial trial populations.

States are making the call differently. The patchwork reflects ongoing policy reckoning, not a settled answer.

Decision framework

If your state covers Wegovy and you meet BMI criteria: file the PA. Build the file with BMI documentation, comorbidity, and lifestyle intervention history.

If your state does not cover Wegovy: the Fair Hearing will not overturn state policy. Pursue PAP or 503A.

If you are dual-eligible with cardiovascular disease: Part D coverage under the CMS rule is the primary path. Medicaid wraps around.

If you are dual-eligible without cardiovascular disease: only state Medicaid in a covering state provides a Wegovy coverage path.

FAQ

Does Medicaid cover Wegovy? Depends on the state. About 14 states cover for obesity as of May 2026.

Why does it vary? Medicaid is state-administered. Each state chooses whether to cover weight-loss drugs.

Which states cover Wegovy? Massachusetts, Minnesota, Pennsylvania, California, Michigan, Wisconsin, Virginia, New York, Illinois, others.

Which states don't? Texas, Florida, Tennessee, Mississippi, Louisiana, Alabama, Oklahoma, others.

What's the PA criteria? BMI 30+ or BMI 27+ with comorbidity, lifestyle intervention, age 18+.

Renewal criterion? 5% weight loss from baseline at 6 months.

How do I appeal? Medicaid Fair Hearing within 60 to 90 days of the denial.

What about dual-eligibles? Part D for the CV indication; Medicaid wraps around or covers for obesity in covering states.

Sources

1. Centers for Medicare and Medicaid Services. Medicaid Drug Rebate Program. 2026.
2. State Medicaid pharmacy bulletins for 2026.
3. Kaiser Family Foundation. State Medicaid coverage of GLP-1 medications for weight loss. 2026.
4. U.S. Food and Drug Administration. Wegovy prescribing information.
5. Lincoff AM, et al. SELECT cardiovascular outcomes. NEJM. 2023;389:2221-2232.
6. Wilding JPH, et al. STEP 1. NEJM. 2021;384:989-1002.
7. Centers for Medicare and Medicaid Services. Final rule on Part D for cardiovascular indications. November 2024.
8. 42 CFR 431.200 et seq. Medicaid Fair Hearing rights and procedures.
9. Endocrine Society. Obesity pharmacotherapy clinical practice guideline.
10. American Diabetes Association. Standards of Care 2026.
11. Novo Nordisk. Patient Assistance Program eligibility.
12. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians via telehealth. We do not enroll beneficiaries in Medicaid or adjudicate Medicaid claims. State Medicaid policies vary widely and change over time. Information here reflects publicly available materials as of May 2026.

Compounded Medication Notice. Compounded semaglutide is produced by a state-licensed 503A pharmacy for an individual patient based on a prescription. It is not FDA-approved, not equivalent to brand-name Wegovy, and not billable to Medicaid. Decisions belong with a prescribing clinician.

Results Disclaimer. Coverage results depend on state Medicaid policy, MCO rules, and individual clinical documentation. Examples here do not predict outcomes for any specific case.

Trademark Notice. Wegovy, Saxenda, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Qsymia is a registered trademark of Vivus LLC. Contrave is a registered trademark of Currax Pharmaceuticals. Medicaid is a joint federal-state program. FormBlends is independent.